Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Commentary

Commentary on the Article “Multiple Hormonal and Metabolic Deficiency Syndrome Predicts Outcome in Heart Failure: The T.O.S.CA. Registry”, Antonio Cittadini et al. Eur. J. Prev. Cardiol. 2021

Author(s): Vincenzo Triggiani * and Giuseppe Lisco

Volume 22, Issue 6, 2022

Published on: 14 April, 2022

Page: [545 - 548] Pages: 4

DOI: 10.2174/1871530321666211215144023

Abstract

Chronic heart failure represents a relevant concern for public health. The endocrine system is heavily involved in the induction and progression of chronic heart failure. Among endocrine disorders, the most relevant alterations are related to the growth hormone-insulin like growth factor 1 axis, serum testosterone, dehydroepiandrosterone sulfate, triiodothyronine levels, insulin resistance, and type 2 diabetes mellitus. It is currently debated whether these changes might be simple adaptive mechanisms or, instead, they may deteriorate myocardial pump function over time. In this commentary on a recently published paper by Antonio Cittadini et al. (Eur J Prev Cardiol. 2021), we briefly presented and discussed data form the “Trattamento Ormonale nello Scompenso CArdiaco; Hormone Treatment in Heart Failure (TOSCA) Registry”. One or more hormonal deficiencies or metabolic disorders, including insulin resistance and diabetes mellitus, were more commonly diagnosed in patients with heart failure (358 patients, 75% of study group). The presence of multiple hormone deficiency identified a subset of patients at increased risk of hospitalization and death, with a graded relation between the number of deficiencies and total events. This finding suggests a possible causal role of hormone deficiencies in CHF progression. Screening of hormonal and metabolic imbalances in CHF patients would be an interesting opportunity for improving the prognosis of patients with heart failure as it would identify high-risk patients requiring an additional medical management of the underlying endocrine and metabolic disorders.

Keywords: Multiple hormonal and metabolic deficiency syndrome, chronic heart failure, testosterone, growth hormone, insulin-like growth factor, triiodothyronine, dehydroepiandrosterone sulfate, insulin resistance, diabetes mellitus.

Next »
[1]
Cittadini, A.; Salzano, A.; Iacoviello, M.; Triggiani, V.; Rengo, G.; Cacciatore, F.; Maiello, C.; Limongelli, G.; Masarone, D.; Perticone, F.; Cimellaro, A.; Perrone Filardi, P.; Paolillo, S.; Mancini, A.; Volterrani, M.; Vriz, O.; Castello, R.; Passantino, A.; Campo, M.; Modesti, P.A.; De Giorgi, A.; Monte, I.P.; Puzzo, A.; Ballotta, A.; D'Assante, R.; Arcopinto, M.; Gargiulo, P.; Sciacqua, A.; Bruzzese, D.; Colao, A.; Napoli, R.; Suzuki, T.; Eagle, K.A.; Ventura, H.O.; Marra, A.M.; Bossone, E. Multiple hormonal and metabolic deficiency syndrome predicts outcome in heart failure: the T.O.S.CA.Registry. Eur. J. Prev. Cardiol., 2021, 28(15), 1691-1700.
[http://dx.doi.org/10.1093/eurjpc/zwab020]
[2]
Bossone, E.; Arcopinto, M.; Iacoviello, M.; Triggiani, V.; Cacciatore, F.; Maiello, C.; Limongelli, G.; Masarone, D.; Perticone, F.; Sciacqua, A.; Perrone-Filardi, P.; Mancini, A.; Volterrani, M.; Vriz, O.; Castello, R.; Passantino, A.; Campo, M.; Modesti, P.A.; De Giorgi, A.; Monte, I.; Puzzo, A.; Ballotta, A.; Caliendo, L.; D’Assante, R.; Marra, A.M.; Salzano, A.; Suzuki, T.; Cittadini, A. TOSCA Investigators. Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.CA. Registry. Intern. Emerg. Med., 2018, 13(5), 661-671.
[http://dx.doi.org/10.1007/s11739-018-1844-8] [PMID: 29619769]
[3]
Chan, D.Z.L.; Kerr, A.J.; Doughty, R.N. Temporal trends in the burden of heart failure. Intern. Med. J., 2021, 51(8), 1212-1218.
[http://dx.doi.org/10.1111/imj.15253] [PMID: 33650267]
[4]
Iacoviello, M.; Triggiani, V. Editorial (hot topic: introduction to the special issue: relevance of endocrine and metabolic disorders in heart failure: from pathophysiology to therapeutic approach). Endocrine Metab. Immune Disord. Targets, 2013, 13(1), 2-3.
[http://dx.doi.org/10.2174/1871530311313010002]
[5]
Triggiani, V.; Iacoviello, M. Thyroid disorders in chronic heart failure: from prognostic set-up to therapeutic management. Immune Disord. Targets, 2013, 13(1), 22-37.
[http://dx.doi.org/10.2174/1871530311313010005] [PMID: 23369135]
[6]
Triggiani, V.; Angelo Giagulli, V.; De Pergola, G.; Licchelli, B.; Guastamacchia, E.; Iacoviello, M. Mechanisms explaining the influence of subclinical hypothyroidism on the onset and progression of chronic heart failure. Endocr. Metab. Immune Disord. Drug Targets, 2016, 16(1), 2-7.
[http://dx.doi.org/10.2174/1871530316666151218151319] [PMID: 26680772]
[7]
Iacoviello, M.; Parisi, G.; Gioia, M.I.; Grande, D.; Rizzo, C.; Guida, P.; Lisi, F.; Giagulli, V.A.; Licchelli, B.; Di Serio, F.; Guastamacchia, E.; Triggiani, V. Thyroid disorders and prognosis in chronic heart failure: A long-term follow-up study. Endocr. Metab. Immune Disord. Drug Targets, 2020, 20(3), 437-445.
[http://dx.doi.org/10.2174/1871530319666191018134524] [PMID: 31656160]
[8]
Rizzo, C.; Gioia, M.I.; Parisi, G.; Triggiani, V.; Iacoviello, M. Dysthyroidism and chronic heart failure: Pathophysiological mechanisms and therapeutic approaches. Adv. Exp. Med. Biol., 2018, 1067, 239-253.
[http://dx.doi.org/10.1007/5584_2017_132] [PMID: 29235066]
[9]
Ning, N.; Gao, D.; Triggiani, V.; Iacoviello, M.; Mitchell, J.E.; Ma, R.; Zhang, Y.; Kou, H. Prognostic role of hypothyroidism in heart failure: A meta-analysis. Medicine (Baltimore), 2015, 94(30), e1159.
[http://dx.doi.org/10.1097/MD.0000000000001159] [PMID: 26222845]
[10]
Gencer, B.; Collet, T.H.; Virgini, V.; Bauer, D.C.; Gussekloo, J.; Cappola, A.R.; Nanchen, D.; den Elzen, W.P.; Balmer, P.; Luben, R.N.; Iacoviello, M.; Triggiani, V.; Cornuz, J.; Newman, A.B.; Khaw, K.T.; Jukema, J.W.; Westendorp, R.G.; Vittinghoff, E.; Aujesky, D.; Rodondi, N. Thyroid studies collaboration. subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation, 2012, 126(9), 1040-1049.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.096024] [PMID: 22821943]
[11]
Triggiani, V.; Iacoviello, M.; Monzani, F.; Puzzovivo, A.; Guida, P.; Forleo, C.; Ciccone, M.M.; Catanzaro, R.; Tafaro, E.; Licchelli, B.; Giagulli, V.A.; Guastamacchia, E.; Favale, S. Incidence and prevalence of hypothyroidism in patients affected by chronic heart failure: role of amiodarone. Endocr. Metab. Immune Disord. Drug Targets, 2012, 12(1), 86-94.
[http://dx.doi.org/10.2174/187153012799278947] [PMID: 22214334]
[12]
Iacoviello, M.; Guida, P.; Guastamacchia, E.; Triggiani, V.; Forleo, C.; Catanzaro, R.; Cicala, M.; Basile, M.; Sorrentino, S.; Favale, S. Prognostic role of sub-clinical hypothyroidism in chronic heart failure outpatients. Curr. Pharm. Des., 2008, 14(26), 2686-2692.
[http://dx.doi.org/10.2174/138161208786264142] [PMID: 19006851]
[13]
Terlizzese, P.; Albanese, M.; Grande, D.; Parisi, G.; Gioia, M.I.; Brunetti, N.D.; Lisi, F.; Lisco, G.; Di Serio, F.; Ciccone, M.M.; Triggiani, V.; Iacoviello, M. TSH variations in chronic heart failure outpatients: clinical correlates and outcomes. Endocr. Metab. Immune Disord. Drug Targets, 2021, 21(10), 1935-1942.
[http://dx.doi.org/10.2174/1871530321666210430131510] [PMID: 33938411]
[14]
Giagulli, V.A.; Guastamacchia, E.; De Pergola, G.; Iacoviello, M.; Triggiani, V. Testosterone deficiency in male: a risk factor for heart failure. Endocr. Metab. Immune Disord. Drug Targets, 2013, 13(1), 92-99.
[http://dx.doi.org/10.2174/1871530311313010011] [PMID: 23369141]
[15]
Dei Cas, A.; Khan, S.S.; Butler, J.; Mentz, R.J.; Bonow, R.O.; Avogaro, A.; Tschoepe, D.; Doehner, W.; Greene, S.J.; Senni, M.; Gheorghiade, M.; Fonarow, G.C. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail., 2015, 3(2), 136-145.
[http://dx.doi.org/10.1016/j.jchf.2014.08.004] [PMID: 25660838]
[16]
De Pergola, G.; Nardecchia, A.; Giagulli, V.A.; Triggiani, V.; Guastamacchia, E.; Minischetti, M.C.; Silvestris, F. Obesity and heart failure. Endocr. Metab. Immune Disord. Drug Targets, 2013, 13(1), 51-57.
[http://dx.doi.org/10.2174/1871530311313010007] [PMID: 23369137]
[17]
Zamboni, M.; Rossi, A.P.; Corzato, F.; Bambace, C.; Mazzali, G.; Fantin, F. Sarcopenia, cachexia and congestive heart failure in the elderly. Endocr. Metab. Immune Disord. Drug Targets, 2013, 13(1), 58-67.
[http://dx.doi.org/10.2174/1871530311313010008] [PMID: 23369138]
[18]
Arcopinto, M.; Salzano, A.; Isgaard, J.; Cittadini, A. Hormone replacement therapy in heart failure. Curr. Opin. Cardiol., 2015, 30(3), 277-284.
[http://dx.doi.org/10.1097/HCO.0000000000000166] [PMID: 25807222]
[19]
Grande, D.; Terlizzese, P.; Gioia, M.I.; Parisi, G.; Giagulli, V.A.; Triggiani, V.; Iacoviello, M. New frontiers in the therapeutic approach of patients with cardiovascular and endocrine diseases. Endocr. Metab. Immune Disord. Drug Targets, 2019, 19(5), 605-621.
[http://dx.doi.org/10.2174/1871530319666190101151542] [PMID: 30621568]
[20]
Giagulli, V.A.; Moghetti, P.; Kaufman, J.M.; Guastamacchia, E.; Iacoviello, M.; Triggiani, V. Managing erectile dysfunction in heart failure. Endocr. Metab. Immune Disord. Drug Targets, 2013, 13(1), 125-134.
[http://dx.doi.org/10.2174/1871530311313010015] [PMID: 23369145]
[21]
Mann, D.L. Mechanisms and models in heart failure: A combinatorial approach. Circulation, 1999, 100(9), 999-1008.
[http://dx.doi.org/10.1161/01.CIR.100.9.999] [PMID: 10468532]
[22]
Fiore, G.; Suppress, P.; Triggiani, V.; Resta, F.; Sabbà, C. Neuroimmune activation in chronic heart failure. Endocr. Metab. Immune Disord. Drug Targets, 2013, 13(1), 68-75.
[http://dx.doi.org/10.2174/1871530311313010009] [PMID: 23369139]
[23]
Iovino, M.; Iacoviello, M.; De Pergola, G.; Licchelli, B.; Iovino, E.; Guastamacchia, E.; Giagulli, V.A.; Triggiani, V. Vasopressin in heart failure. Endocr. Metab. Immune Disord. Drug Targets, 2018, 18(5), 458-465.
[http://dx.doi.org/10.2174/1871530318666180212095235] [PMID: 29437026]
[24]
Jankowska, E.A.; Biel, B.; Majda, J.; Szklarska, A.; Lopuszanska, M.; Medras, M.; Anker, S.D.; Banasiak, W.; Poole-Wilson, P.A.; Ponikowski, P. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation, 2006, 114(17), 1829-1837.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.649426] [PMID: 17030678]
[25]
Arcopinto, M.; Salzano, A.; Bossone, E.; Ferrara, F.; Bobbio, E.; Sirico, D.; Vriz, O.; De Vincentiis, C.; Matarazzo, M.; Saldamarco, L.; Saccà, F.; Napoli, R.; Iacoviello, M.; Triggiani, V.; Isidori, A.M.; Vigorito, C.; Isgaard, J.; Cittadini, A. Multiple hormone deficiencies in chronic heart failure. Int. J. Cardiol., 2015, 184, 421-423.
[http://dx.doi.org/10.1016/j.ijcard.2015.02.055] [PMID: 25755056]
[26]
Arcopinto, M.; Salzano, A.; Giallauria, F.; Bossone, E.; Isgaard, J.; Marra, A.M.; Bobbio, E.; Vriz, O.; Åberg, D.N.; Masarone, D.; De Paulis, A.; Saldamarco, L.; Vigorito, C.; Formisano, P.; Niola, M.; Perticone, F.; Bonaduce, D.; Saccà, L.; Colao, A.; Cittadini, A. T.O.S.CA. (Trattamento Ormonale Scompenso CArdiaco) Investigators. Growth hormone deficiency is associated with worse cardiac function, physical performance, and outcome in chronic heart failure: Insights from the T.O.S.CA. GHD Study. PLoS One, 2017, 12(1), e0170058.
[http://dx.doi.org/10.1371/journal.pone.0170058] [PMID: 28095492]
[27]
Lisco, G.; De Tullio, A.; Iacoviello, M.; Triggiani, V. Congestive heart failure and thyroid dysfunction: The role of the low T3 syndrome and therapeutic aspects. Endocr. Metab. Immune Disord. Drug Targets, 2020, 20(5), 646-653.
[http://dx.doi.org/10.2174/1871530319666191119112950] [PMID: 31742499]
[28]
Niebauer, J.; Pflaum, C.D.; Clark, A.L.; Strasburger, C.J.; Hooper, J.; Poole-Wilson, P.A.; Coats, A.J.; Anker, S.D. Deficient insulin like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J. Am. Coll. Cardiol., 1998, 32(2), 393-397.
[http://dx.doi.org/10.1016/S0735-1097(98)00226-5] [PMID: 9708466]
[29]
Anker, S.D.; Volterrani, M.; Pflaum, C.D.; Strasburger, C.J.; Osterziel, K.J.; Doehner, W.; Ranke, M.B.; Poole-Wilson, P.A.; Giustina, A.; Dietz, R.; Coats, A.J. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J. Am. Coll. Cardiol., 2001, 38(2), 443-452.
[http://dx.doi.org/10.1016/S0735-1097(01)01385-7] [PMID: 11499736]
[30]
D’Assante, R.; Napoli, R.; Salzano, A.; Pozza, C.; Marra, A.M.; Arcopinto, M.; Perruolo, G.; Milano, S.; Formisano, P.; Saldamarco, L.; Cirillo, P.; Cittadini, A. Human heart shifts from IGF-1 production to utilization with chronic heart failure. Endocrine, 2019, 65(3), 714-716.
[http://dx.doi.org/10.1007/s12020-019-01993-y] [PMID: 31267324]
[31]
D’Assante, R.; Arcopinto, M.; Rengo, G.; Salzano, A.; Walser, M.; Gambino, G.; Monti, M.G.; Bencivenga, L.; Marra, A.M.; Åberg, D.N.; De Vincentiis, C.; Ballotta, A.; Bossone, E.; Isgaard, J.; Cittadini, A. Myocardial expression of somatotropic axis, adrenergic signalling, and calcium handling genes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. ESC Heart Fail., 2021, 8(2), 1681-1686.
[http://dx.doi.org/10.1002/ehf2.13067] [PMID: 33512777]
[32]
Caminiti, G.; Volterrani, M.; Iellamo, F.; Marazzi, G.; Massaro, R.; Miceli, M.; Mammi, C.; Piepoli, M.; Fini, M.; Rosano, G.M. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J. Am. Coll. Cardiol., 2009, 54(10), 919-927.
[http://dx.doi.org/10.1016/j.jacc.2009.04.078] [PMID: 19712802]
[33]
Oh, J.Y.; Barrett-Connor, E.; Wedick, N.M.; Wingard, D.L. Rancho Bernardo Study. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care, 2002, 25(1), 55-60.
[http://dx.doi.org/10.2337/diacare.25.1.55] [PMID: 11772901]
[34]
Iervasi, G.; Pingitore, A.; Landi, P.; Raciti, M.; Ripoli, A.; Scarlattini, M.; L’Abbate, A.; Donato, L. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation, 2003, 107(5), 708-713.
[http://dx.doi.org/10.1161/01.CIR.0000048124.64204.3F] [PMID: 12578873]
[35]
Pingitore, A.; Galli, E.; Barison, A.; Iervasi, A.; Scarlattini, M.; Nucci, D.; L’abbate, A.; Mariotti, R.; Iervasi, G. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J. Clin. Endocrinol. Metab., 2008, 93(4), 1351-1358.
[http://dx.doi.org/10.1210/jc.2007-2210] [PMID: 18171701]
[36]
Banerjee, D.; Biggs, M.L.; Mercer, L.; Mukamal, K.; Kaplan, R.; Barzilay, J.; Kuller, L.; Kizer, J.R.; Djousse, L.; Tracy, R.; Zieman, S.; Lloyd-Jones, D.; Siscovick, D.; Carnethon, M. Insulin resistance and risk of incident heart failure: Cardiovascular Health Study. Circ. Heart Fail., 2013, 6(3), 364-370.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.112.000022] [PMID: 23575256]
[37]
Salzano, A.; Marra, A.M.; Arcopinto, M.; D’Assante, R.; Triggiani, V.; Coscioni, E.; Pasquali, D.; Rengo, G.; Suzuki, T.; Bossone, E.; Cittadini, A. Combined effects of growth hormone and testosterone replacement treatment in heart failure. ESC Heart Fail., 2019, 6(6), 1216-1221.
[http://dx.doi.org/10.1002/ehf2.12520] [PMID: 31696666]

Rights & Permissions Print Cite
Article Metrics
11
1
© 2024 Bentham Science Publishers | Privacy Policy